Senator Bernie Sanders

Although GLP-1 weight-loss drugs are delivering impressive results, the big concern is the high price of treatment – and who pays for it. Sen. Bernie Sanders, I-Vt., has weighed in on the debate by calling on Novo Nordisk to lower the price of its popular drugs Ozempic and Wegovy, and wants to meet with the drugmakers's CEO Lars Fruergaard Jorgensen over the costs of GLP-1 drugs for diabetes and obesity.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Cost-Containment
Employee Participation
Employee-Paid